Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Biliary Tract Neoplasms 5Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Advanced or Metastatic Solid Tumors 3Uterine Cervical Neoplasms 2Solid Tumors 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Rare Tumour 1Prostatic Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Carcinoma 1Histiocytoma, Malignant Fibrous 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × envafolimab × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡